constipation%20in%20children
CONSTIPATION IN CHILDREN

Constipation is a delay or difficulty in bowel movement persisting for ≥2 weeks.
It is a common digestive problem, not a disease, and usually not serious caused by changes in diet and early toilet training.
Constipation in children generally first happens in the toddler stage, between ages 2 and 4 years, with studies showing variation in gender-specific prevalence.
Functional constipation is  the one that cannot be explained by any anatomical, physiological, radiological or histological abnormalities.
Organic constipation is with identifiable physiological or organic cause.
Chronic constipation is the constipation that lasts for >8 weeks.

Constipation%20in%20children Management

Follow Up

  • Since relapses are common and bowel movement difficulty may persist into adolescence, follow-up plan of children and their parents should be individualized, tailored based on the child’s treatment response measured by consistency, frequency, and amount of stool
  • Discuss preventive measures for relapse of constipation

Prognosis

  • In a recent systematic review, majority of children with constipation recover within 6-12 months of starting treatment and recovery rate is not related to age of onset, frequency of bowel movement, positive family history, and presence of fecal incontinence
  • Another study noted that less than half of affected children continued to be symptomatic beyond puberty with associated several complications
  • Relapse rate is high as functional constipation is difficult to treat
  • Underlying organic disorders exacerbate constipation resulting in difficult long-term management

Timing

  • Advise parents/guardians of infants <6 months with functional constipation to bring patient for follow-up after 2-4 weeks and infants ≥6 months with functional constipation without fecal impaction after 2 weeks for re-evaluation and evaluation of treatment efficacy

Specialist Referral

  • Consultation with a pediatric gastroenterologist is indicated if the child’s history or exam findings suggest an organic cause, when the child fails therapy, or for complex management
  • Symptoms not improving after 6 months of good compliance to therapy warrants a pediatric gastroenterology consult
    • The pediatric gastroenterologist further evaluates the child for underlying organic problems, does specialized tests, and gives counseling; review of previous treatment regimen may lead to adjustment of medications
  • Referral to pediatric surgeon may be considered for patients unresponsive to extensive medical management
    • Surgical management of refractory functional constipation may include anal procedures (eg botulinum toxininjection, sphincter myectomy), antegrade continence enema, colorectal resection, and intestinal diversion
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 4 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.